Curis Inc (CRIS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Ali Fattaey
Employees:
31
4 MAGUIRE ROAD, LEXINGTON, MA 02421
617-503-6500

Curis, Inc. is a biotechnology company, which is focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. Its pipeline includes is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes. It conducts research programs both internally and through strategic collaborations. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Data derived from most recent annual or quarterly report
Market Cap 645.754 Million Shares Outstanding91.596 Million Avg 30-day Volume 942.42 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.15
Price to Revenue31.4986 Debt to Equity0.0 EBITDA-33.382 Million
Price to Book Value2.6665 Operating Margin-358.9646 Enterprise Value217.946 Million
Current Ratio7.516 EPS Growth0.721 Quick Ratio6.953
1 Yr BETA 52-week High/Low 17.4 / 1.06 Profit Margin-363.205
Operating Cash Flow Growth-45.7097 Altman Z-Score13.1882 Free Cash Flow to Firm -55.319 Million
View SEC Filings from CRIS instead.

View recent insider trading info

Funds Holding CRIS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CRIS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GREENACRE MARTYN D

  • Director
0 2021-01-28 1

KAITIN KENNETH I

  • Director
0 2021-01-28 1

DENTZER JAMES E PRESIDENT & CEO

  • Officer
  • Director
0 2021-01-28 2

RUBIN MARC

  • Director
0 2021-01-28 1

MARTELL ROBERT HEAD OF RESEARCH & DEVELOPMENT

  • Officer
0 2021-01-28 1

KUNKEL LORI ANNE

  • Director
0 2021-01-28 1

STEINKRAUSS WILLIAM CHIEF FINANCIAL OFFICER

  • Officer
0 2021-01-28 1

NOEL MARK VICE-PRESIDENT

  • Officer
0 2020-02-02 0

FATTAEY ALI PH.D. PRESIDENT & CEO

  • Officer
  • Director
0 2018-05-15 0

TUCK DAVID CHIEF MEDICAL OFFICER

  • Officer
0 2018-05-15 0

MCNAB JAMES R

  • Director
929,688 2017-05-03 0

PIENTA KENNETH

  • Director
0 2017-02-28 0

MOHINDRU MANI CHIEF STRATEGY OFFICER

  • Officer
0 2017-02-14 0

PASSERI DANIEL R

  • Director
0 2016-01-19 0

GRAY MICHAEL CFO

  • Officer
0 2015-05-27 0

VINER JAYE CHIEF MEDICAL OFFICER

  • Officer
0 2015-05-27 0

TOBIN JAMES R

  • Director
0 2015-01-26 0

AURIGENE DISCOVERY TECHNOLOGIES LTD

DR REDDYS LABORATORIES LTD

  • 10% Owner
17,120,131 2015-01-18 0

AURIGENE DISCOVERY TECHNOLOGIES LTD

DR REDDYS LABORATORIES LTD

DR. REDDY'S HOLDINGS LTD

  • 10% Owner
27,328,464 2015-01-18 0

BAYH SUSAN B

  • Director
0 2013-01-17 0

VOI MAURIZIO CHIEF MEDICAL OFFICER

  • Officer
0 2013-01-17 0

DAVIE JOSEPH MD PHD

  • Director
0 2011-01-07 0

QIAN CHANGGENG VP, RESEARCH & PRECLINICAL DEV

  • Officer
0 2011-01-07 0

KEEGAN MITCHELL VICE-PRESIDENT

  • Officer
0 2011-01-07 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
No longer subject to file 2009-04-27 0

RA CAPITAL MANAGEMENT, LLC

RA CAPITAL BIOTECH FUND LP

RA CAPITAL BIOTECH FUND II, L.P.

ALDRICH RICHARD

KOLCHINSKY PETER

  • 10% Owner
No longer subject to file 2008-04-15 0

CARTER STEPHEN

  • Director
0 2008-01-25 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CURIS INC CRIS 2021-10-26 22:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 21:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 21:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 20:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 20:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 19:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 19:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 18:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 18:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 17:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 17:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 16:45:04 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 16:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 15:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 15:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 14:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 14:15:05 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 13:45:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 13:15:03 UTC -0.3598 0.4298 1200000
CURIS INC CRIS 2021-10-26 12:45:03 UTC -0.3598 0.4298 1100000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund CRIS -422.0 shares, $-3405.54 2021-06-30 N-PORT
Weiss Strategic Interval Fund- Weiss Strategic Interval Fund CRIS -1478.0 shares, $-11927.46 2021-06-30 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CRIS -2000.0 shares, $-16140.0 2021-06-30 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund CRIS -2625.0 shares, $-19923.75 2021-07-31 N-PORT

Short Position History (International Only)

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC Curis Inc 0.8% 2018-11-30 GERMANY
Squarepoint Ops LLC Curis Inc 0.9% 2018-12-20 GERMANY
Squarepoint Ops LLC Curis Inc 0.78% 2018-11-07 GERMANY

Elevate your investments